Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP & Chief Financial Officer | September 30, 2026 | October 03, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Executive VP & CFO | October 11, 2024 | October 15, 2024 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Executive Vice President & COO | July 01, 2022 | July 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,762 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 10 · Balance 27,762 F1: The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period.
DENTSPLY SIRONA Inc.
Report date October 11, 2024 · Filed October 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,767.654 |
Reported balance
After 2024-10-11 transaction · row 1
1 source rowRow 1 · 2024-10-11 · Grant · Acquired 375.279 · Balance 89,767.654 F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. |
| Phantom Stock (Supplemental Executive Retirement Plan) SERPSEC Table II · derivative / convertible security | Direct | 1,892.0687 |
Reported balance
After 2024-10-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-11 · Grant · Acquired 12.2776 · Balance 1,892.0687 F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting persons termination of employment. F3: Comprised of phantom stock acquired as a result of accrued dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting persons termination of employment.
F3: Comprised of phantom stock acquired as a result of accrued dividends.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date July 01, 2022 · Filed July 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,622 |
Reported balance
After 2022-07-01 transaction · row 1
1 source rowRow 1 · 2022-07-01 · Tax withholding · Disposed 6,666 · Balance 34,622 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Premier, Inc.
Report date November 25, 2025 · Filed November 26, 2025
Section 16 reporting ended · disclosed 2025-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-11-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-11-25 · Disposition to issuer · Disposed 161,464 · Balance 32,018 F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement. F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents). Row 2 · 2025-11-25 · Disposition to issuer · Disposed 32,018 · Balance 0 F3: Reflects the cancellation at the Effective Time of RSUs granted to the reporting person on or after August 16, 2025. Pursuant to the Merger Agreement, these RSUs were cancelled in connection with the Merger for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement.
F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents).
F3: Reflects the cancellation at the Effective Time of RSUs granted to the reporting person on or after August 16, 2025. Pursuant to the Merger Agreement, these RSUs were cancelled in connection with the Merger for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,634 | $56.14 | $91,732.76 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 7 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,417 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 436 | $56.14 | $24,477.04 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 6 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,051 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 5,717 | $56.05 | $320,444.71 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 5 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,487 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $56.05 to $56.09. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,052 | $56.20 | $171,522.40 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 4 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,204 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,108 | $0.00 Strike: $56.23 | $0.00 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · derivative · entry 8 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,108 Underlying: Common Stock · 17,108 shares Expires 2026-03-13 F2 · derivative.exercise_date: 33% of the shares of stock options will vest each of the first and second anniversaries of the grant date of 3/13/2018 and 34% of the shares of stock options will vest on the third anniversary of the grant date of 3/13/2018. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 4,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,256 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 2,002 | $56.23 | $112,572.46 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,838 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 534 | $56.23 | $30,026.82 |
DisclosureSEC source: 0001209191-18-019837 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,840 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:26 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011346 · doc4.xml · nonDerivative · entry 4 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,374 F4 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2018 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:26 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 5,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011346 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,858 F3 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2018 at 150% target, the second anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:26 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011346 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,542 F2 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 34% of the shares will vest on March 23, 2018, the third anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:26 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 9,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011346 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,536 F1 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least a 3% increase in annual revenue over the prior fiscal year, under the May 2, 2014 Performance Stock Award. Accordingly, 25% of the shares will vest on May 2, 2018, the fourth anniversary of the grant date. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:51 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 13,865 | $45.91 | $636,517.19 |
DisclosureSEC source: 0001209191-17-030370 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,519 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $45.90 to $45.94. Read SEC document |
| May 02, 2017 Filed May 3, 2017 20:41 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,871 | $46.44 | $86,889.24 |
DisclosureSEC source: 0001209191-17-029697 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,384 Read SEC document |
| May 02, 2017 Filed May 3, 2017 20:41 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 4,676 | $46.44 | $217,153.44 |
DisclosureSEC source: 0001209191-17-029697 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,255 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 984 | $42.35 | $41,672.40 |
DisclosureSEC source: 0001209191-17-023007 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,931 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 23:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 394 | $42.35 | $16,685.90 |
DisclosureSEC source: 0001209191-17-023007 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,915 Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:24 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,462 | $43.19 | $192,733.41 |
DisclosureSEC source: 0001209191-17-021388 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,309 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $43.1901 to $43.2106. Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 479 | $43.03 | $20,611.37 |
DisclosureSEC source: 0001209191-17-020779 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,771 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,793 | $43.03 | $77,152.79 |
DisclosureSEC source: 0001209191-17-020779 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,250 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,354 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-17-020779 · doc4.xml · derivative · entry 4 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,354 Underlying: Common Stock · 20,354 shares Expires 2025-03-13 F1 · derivative.exercise_date: 33% of the shares of stock options will vest each of the first and second anniversaries of the grant date of 3/13/2017 and 34% of the shares of stock options will vest on the third anniversary of the grant date of 3/13/2017. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 5,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020779 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,043 Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:25 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 5,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012104 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,777 F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:25 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012104 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,461 F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:25 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon stock | 9,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012104 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,543 F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date. F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,187 | $0.00 Strike: $76.85 | $0.00 |
DisclosureSEC source: 0001209191-16-153322 · doc4.xml · derivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,187 Underlying: Common Stock · 12,187 shares Expires 2024-12-01 F1 · derivative.exercise_date: 100% of the shares of stock options will vest on the third anniversary of the grant date of 12/01/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.